Principal Investigator
Byron Lam
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20220246
Clinical Trial Summary
Open-label, Multiple Dose, Dose Escalation Study to Evaluate the Safety/Tolerability and Efficacy of EA-2353 in Subjects with Retinitis Pigmentosa
Phase
Phase I/II
Funding Agency/Sponsor
Intramural
Disease
Other